What procurement terms should hospitals negotiate when contracting isotope supply for the Nuclear Medicine Market?

Insist on guaranteed allocation volumes with named backup production sites, not best-efforts language. Contracts should specify penalty terms for missed deliveries, since a failed shipment cancels a full day of scheduled patients [6]. Read More

How should investors distinguish durable radiopharmaceutical assets from speculative ones?

Look for control of isotope feedstock or a signed multi-year irradiation contract. Companies with promising molecules but no secured supply face a hard ceiling on commercialisation regardless of trial results [5]. Read More

What integration challenges do hospitals face when adding therapeutic capability to the Nuclear Medicine Market service line?

Shielded inpatient rooms, waste decay storage, and licensed authorised-user physicians are prerequisites that typically take 12 to 18 months to establish. Underestimating the licensing timeline is the most common planning failure [20]. Read More

Is targeted alpha therapy clinically superior to beta-emitter therapy?

Alpha emitters deliver higher energy over a shorter path, potentially sparing healthy tissue and overcoming beta resistance. Comparative head-to-head evidence remains limited, so superiority claims are premature [7]. Read More

How does dosimetry affect the economics of a therapy programme?

Individualised dosimetry adds imaging sessions and physicist time per cycle, raising per-patient cost. Regulators increasingly expect it, so budget for the added workflow rather than treating it as optional [15]. Read More

Which emerging clinical use cases could reshape the Nuclear Medicine Market after 2030?

Fibroblast activation protein imaging shows promise across multiple solid tumours, and infection-specific tracers could reduce diagnostic uncertainty in prosthetic joint cases. Both remain investigational today [21]. Read More

What regulatory nuance most often surprises new market entrants?

Radiopharmaceuticals face dual oversight — pharmaceutical approval plus radiation-materials licensing — administered by separate agencies with unsynchronised timelines. Filing sequencing errors routinely delay launches by several quarters [15] [20]. Read More

Nuclear Medicine Market (2026 - 2035)

ID: MRFR/HC/5211-CR 200 Pages Rahul Gotadki Last Updated: September 15, 2026

Nuclear Medicine Market Research Report: Size, Share, Trend Analysis By Applications (Diagnostic Imaging, Therapeutic Applications, Radiopharmaceutical Production, Research Applications), By Radioisotope Type (Technetium-99m, Iodine-131, Fluorine-18, Yttrium-90), By End Users (Hospitals, Diagnostic Imaging Centers, Academic Research Institutions, Pharmaceutical Companies), By Procedure (Positron Emission Tomography, Single-Photon Emission Computed Tomography, Radiotherapy, Brachytherapy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Nuclear Medicine Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)13.4%

2025 Market SizeUSD 18.63 Billion

2035 Market SizeUSD 65.04 Billion

Key Players

Curium Pharma

Lantheus Holdings

Novartis

Cardinal Health Nuclear & Precision Health

GE HealthCare

Bracco Imaging

Trends

Precision Oncology Treatment Conversion
Reimbursement Architecture Reform
Isotope Supply Security

Opportunities

Alpha-Emitter Therapeutics Commercialisation
Diagnostic-Therapeutic Pairing as a Platform Model
Emerging-Market Access Programmes

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 By Technology (Product Type & Radioisotope) |
2. 2.2 By Sector (Application & End User) |
3. 2.3 By Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Drivers Analysis |
1. 4.1 Precision Oncology Treatment Conversion |
2. 4.2 Reimbursement Architecture Reform |
3. 4.3 Isotope Supply Security |
4. 4.4 Ageing Demographics and Cardiac Demand
5 Market Restraints Analysis |
1. 5.1 The Tyranny of Half-Life |
2. 5.2 Capital Barriers in Emerging Economies |
3. 5.3 Workforce Constraints
6 Market Opportunity Analysis |
1. 6.1 Alpha-Emitter Therapeutics Commercialisation |
2. 6.2 Diagnostic-Therapeutic Pairing as a Platform Model |
3. 6.3 Emerging-Market Access Programmes |
4. 6.4 Dosimetry Data and Software Monetisation |
5. 6.5 Decentralised Production Networks
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Algorithmic Quantification Becomes Standard of Care |
2. 8.2 Vertical Integration of Isotope Supply |
3. 8.3 Reimbursement Convergence Across Advanced Economies |
4. 8.4 Sustainability and Waste Stewardship Reporting
9 Segmentation Analysis |
1. 9.1 By Product Type | |
  1. 9.1.1 Diagnostics | |
  2. 9.1.2 Therapeutics |
2. 9.2 By Radioisotope | |
  1. 9.2.1 Technetium-99m | |
  2. 9.2.2 Fluorine-18 | |
  3. 9.2.3 Iodine-131 | |
  4. 9.2.4 Lutetium-177 | |
  5. 9.2.5 Others |
3. 9.3 By Application | |
  1. 9.3.1 Oncology | |
  2. 9.3.2 Cardiology | |
  3. 9.3.3 Neurology | |
  4. 9.3.4 Thyroid | |
  5. 9.3.5 Others |
4. 9.4 By End User | |
  1. 9.4.1 Hospitals | |
  2. 9.4.2 Diagnostic Imaging Centres | |
  3. 9.4.3 Research Institutes | |
  4. 9.4.4 Specialised Radiopharmacies | |
  5. 9.4.5 Others
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Industry Value Chain Analysis |
4. 10.4 Porter's Five Forces Analysis |
5. 10.5 Company Profiles | |
  1. 10.5.1 Curium Pharma | |
  2. 10.5.2 Lantheus Holdings | |
  3. 10.5.3 Novartis (Advanced Accelerator Applications) | |
  4. 10.5.4 Cardinal Health Nuclear & Precision Health | |
  5. 10.5.5 GE HealthCare | |
  6. 10.5.6 Bracco Imaging | |
  7. 10.5.7 Telix Pharmaceuticals | |
  8. 10.5.8 Jubilant Radiopharma | |
  9. 10.5.9 Bayer AG | |
  10. 10.5.10 Eli Lilly (POINT Biopharma) | |
  11. 10.5.11 BWXT Medical | |
  12. 10.5.12 NorthStar Medical Radioisotopes
11 Recent Developments & News
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Valuation Currency & Assumptions |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions (FAQs)
15 LIST OF TABLES
16 LIST OF FIGURES

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product Type	Diagnostics, Therapeutics	Diagnostics	Therapeutics
By Radioisotope	Technetium-99m, Fluorine-18, Iodine-131, Lutetium-177, Others	Technetium-99m	Lutetium-177
By Application	Oncology, Cardiology, Neurology, Thyroid, Others	Oncology	Neurology
By End User	Hospitals, Diagnostic Imaging Centres, Research Institutes, Specialised Radiopharmacies, Others	Hospitals	Specialised Radiopharmacies
By Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Diagnostics	Volume growth steady; digital detector upgrades and AI reporting compress cost per scan
Therapeutics	Value growth accelerating; label expansions convert systemic-therapy budgets into isotope spend

Diagnostics remain the volume engine and will keep expanding in absolute terms, but the revenue centre of gravity is migrating toward therapeutics. Suppliers with both halves of a paired offering capture the full patient journey rather than a single encounter.

By Radioisotope

Sub-Segment	Key Trend
Technetium-99m	Non-reactor production reduces outage exposure; share erodes slowly to PET substitution
Fluorine-18	Distribution radius drives site economics; neurological tracers broaden the use base
Iodine-131	Stable thyroid demand; limited growth headroom in mature markets
Lutetium-177	Irradiation slot contracting extends five to seven years as therapy demand scales
Others	Actinium-225 and lead-212 supply expansion unlocks alpha therapy pipelines

Supply architecture, not clinical preference, determines which isotopes scale. Producers investing in accelerator capacity today are effectively buying share for the 2030s.

By Application

Sub-Segment	Key Trend
Oncology	Paired diagnostic-therapeutic protocols multiply encounters per patient
Cardiology	PET perfusion agents substitute into higher-volume centres
Neurology	Anti-amyloid therapy eligibility makes confirmatory imaging mandatory
Thyroid	Mature protocols; growth tracks population and access rather than innovation
Others	Infection and inflammation imaging emerging from research settings

Oncology sets the headline, yet neurology carries the steepest slope because a drug approval converted an optional scan into a treatment prerequisite.

By End User

Sub-Segment	Key Trend
Hospitals	Shielded therapy suites and licensing depth preserve structural advantage
Diagnostic Imaging Centres	Throughput economics favour high-referral urban catchments
Research Institutes	Trial imaging demand rises with pipeline density
Specialised Radiopharmacies	Outsourced compounding relieves hospital capital and staffing pressure
Others	Mobile and ambulatory settings expand access in underserved geographies

Hospitals hold the therapeutic franchise for regulatory reasons that will not change quickly. The interesting shift is upstream, where centralised dose preparation is quietly becoming the sector's most reliable recurring-revenue layer.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”